Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs

Mirjana T Macvanin; Zoran Gluvic; Jelena Radovanovic; Magbubah Essack; Xin Gao; Esma R Isenovic

doi:10.3389/fendo.2023.1124613

Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs

Front Endocrinol (Lausanne). 2023 Mar 7:14:1124613. doi: 10.3389/fendo.2023.1124613. eCollection 2023.

Authors

Mirjana T Macvanin¹, Zoran Gluvic², Jelena Radovanovic¹, Magbubah Essack³, Xin Gao³, Esma R Isenovic¹

Affiliations

¹ Department of Radiobiology and Molecular Genetics, VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
² University Clinical-Hospital Centre Zemun-Belgrade, Clinic of Internal Medicine, Department of Endocrinology and Diabetes, School of Medicine, University of Belgrade, Belgrade, Serbia.
³ King Abdullah University of Science and Technology (KAUST), Computer, Electrical, and Mathematical Sciences and Engineering (CEMSE) Division, Computational Bioscience Research Center (CBRC), Thuwal, Saudi Arabia.

Abstract

Diabetes mellitus (DM) is on the rise, necessitating the development of novel therapeutic and preventive strategies to mitigate the disease's debilitating effects. Diabetic cardiomyopathy (DCMP) is among the leading causes of morbidity and mortality in diabetic patients globally. DCMP manifests as cardiomyocyte hypertrophy, apoptosis, and myocardial interstitial fibrosis before progressing to heart failure. Evidence suggests that non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), regulate diabetic cardiomyopathy-related processes such as insulin resistance, cardiomyocyte apoptosis and inflammation, emphasizing their heart-protective effects. This paper reviewed the literature data from animal and human studies on the non-trivial roles of miRNAs and lncRNAs in the context of DCMP in diabetes and demonstrated their future potential in DCMP treatment in diabetic patients.

Keywords: cardiomyopathy; diabetes; long non-coding RNAs; microRNAs; therapeutic application.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Deoxycytidine Monophosphate
Diabetes Mellitus* / pathology
Diabetic Cardiomyopathies* / pathology
Fibrosis
Humans
MicroRNAs* / genetics
Myocardium / pathology
RNA, Long Noncoding* / genetics

Substances

MicroRNAs
RNA, Long Noncoding
Deoxycytidine Monophosphate

Grants and funding

This work is part of the collaboration between the Department of Radiobiology and Molecular Genetics, “VINČA” Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia, Clinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia, and KAUST. The research was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract No# 451-03-47/2023-01/200017) and King Abdullah University of Science and Technology (KAUST) through grant awards Nos. BAS/1/1624-01-01, FCC/1/1976-20-01, FCC/1/1976-26-01, and Contract No#OSR 4129.